Loading patent…
AssigneeThe Wellcome Trust Limited as Trustee for the Wellcome Trust
InventorsJohn A. Todd, John W. Hess, Charles T. Caskey, Roger D Cox, David Gerhold, Holly Hammond, Patricia Hey, Yoshihiko Kawaguchi, Tony R. Merriman, Michael L. Metzker, Yusuke Nakagawa, Michael S. Phillips, Rebecca C. J. Twells
Estimating the term…
A novel receptor, “LDL-receptor related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.
An isolated polypeptide comprising the amino acid sequence shown in FIG. 5(e) (SEQ ID NO:4).
A polypeptide comprising the amino acid sequence shown in FIG. 5(c) (SEQ ID NO:3).
A fragment of a polypeptide consisting of at least 5 contiguous amino acids of an amino acid sequence selected from the amino acid sequences of FIG. 5(c) (SEQ ID NO:3) and FIG. 5(e) (SEQ ID NO:4).
Dependencies are inferred from the claim text.